Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06266047 · 1 trial · 1 indication
Number of participants with AEs occurring after first dose of study drug. Relatedness to study drug will be assessed by investigator.
Number of subjects with standard safety laboratory test results of potential clinical significance (according to pre-defined criteria).
Absolute values and changes from baseline for the ECG parameters
Absolute values and changes from baseline for blood pressure and pulse rate
All abnormal rhythms will be reviewed by the study physician for the presence of rhythms of potential clinical concern. The time, duration and description of any clinically significant event will be recorded.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| PF-06266047 | EXPERIMENTAL | PF-06266047 |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo |
| PF-06266047 | DRUG | PF-06266047 |
Inclusion Criteria: 1. Healthy female subjects of non-childbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical exa...
PF-06266047 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific therapeutic indication for PF-06266047 has not been disclosed.
PF-06266047 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of PF-06266047 in healthy volunteers.
PF-06266047 is in Phase 1 clinical development. It has completed one Phase 1 trial, NCT02539550, which evaluated safety, tolerability, and pharmacokinetics in healthy adult subjects. No later-phase trials have been reported.
PF-06266047 has been studied in one completed Phase 1 trial, NCT02539550, titled "A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects." The trial enrolled 25 healthy volunteers in Belgium and was randomized, double-blind, and placebo-controlled.
No, PF-06266047 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in healthy volunteers. It remains in clinical development and has not been approved for any indication.